Kantaro’s Semi-Quantitative Antibody Test Kit Receives Health Canada Authorization Under the COVID-19 Interim Order
-COVID-SeroKlir detects both the presence and precise level of neutralizing IgG antibodies with 98.8% sensitivity and 99.6% specificity -Available immediately and can be used in Canadian laboratories without proprietary equipment Kantaro Biosciences, LLC (Kantaro), a joint venture between the Mount Sinai Health …
UK Vivan Therapeutics Secures Expanded Drug Discovery & Development Platform From Mount Sinai Health System in New York
My Personal Therapeutics Ltd. (trading as Vivan Therapeutics), a UK-based company, announces an expansion of its licensed technology rights from Mount Sinai Health System. Scientists at the Icahn School of Medicine at Mount Sinai Center for Personalized Cancer Therapeutics (CPCT) in New …
Meet Charles Mobbs, PhD, of Team Gilga-Med: the Winner of the Mount Sinai Pitch Challenge 2021
Charles Mobbs, PhD, Professor in the Departments of Geriatrics and Palliative Care, Neuroscience, and Medicine at the Icahn School of Medicine at Mount Sinai, won the Mount Sinai Pitch Challenge on May 5 by presenting the healthcare startup Gilga-Med. Read the Q&A …
Kantaro’s COVID-SeroKlir Antibody Test Named as a Finalist for Fast Company’s 2021 World Changing Ideas Awards
Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE: RENX / NASDAQ: RNLX), announced today that COVID-SeroKlir, its semi-quantitative SARS-CoV-2 IgG antibody test, was named as a finalist in the Pandemic Response category of the 2021 …
Trellus Health Announces Experienced Leaders to Drive Next Phase of Growth
Industry veterans from Teladoc Health, Talkspace, Harwood Capital and Polar Capital join executive team and board of directors Trellus Health, a leading resilience-driven connected health solution for chronic conditions, announced several important additions to its executive team and board of directors. The …
Pitch Challenge 2021 Contestant George Foulard, MD, Discusses Platform for Hospital Capacity Management
George Foulard, MD, a Diagnostic Radiology Resident at The Mount Sinai Hospital, is presenting Bedboard at the Mount Sinai Pitch Challenge on May 5. Bedboard, an information technology platform that matches discharged or transferred patients with proper care settings, won the Innovation …
Mount Sinai Venture Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2021
Kantaro Biosciences among top-ranked in the Joint Venture category Mount Sinai Health System announced today that Kantaro Biosciences, LLC, a joint venture with RenalytixAI, has been named to Fast Company’s prestigious annual list of the “World’s Most Innovative Companies” for 2021 and …
Vaxalto Biotherapeutics and Mount Sinai Enter into Exclusive License Agreement for the Development and Commercialization of Novel Immunotherapeutic Oncolytic Viruses for Treatment of Cancer
Vaxalto Biotherapeutics, Inc. (www.vaxalto.com), a pre-clinical stage biotechnology company focused on developing and commercializing novel engineered immunotherapeutic oncolytic viruses, and Mount Sinai Innovation Partners (MSIP), part of the Icahn School of Medicine at Mount Sinai, have partnered to develop novel cancer immunotherapies. Mount Sinai has …
FDA Adds Kantaro’s Semi-Quantitative COVID-19 Antibody Test to Revised Emergency Use Authorization for Convalescent Plasma
COVID-SeroKlir is a high-performance test that detects the presence and precise level of SARS-CoV-2 IgG antibodies NEW YORK, Feb. 10, 2021 — Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE:RENX /NASDAQ: RNLX), and manufacturing partner …